Pyxis Oncology (PYXS) Capital Expenditures (2021 - 2024)

Pyxis Oncology (PYXS) has 4 years of Capital Expenditures data on file, last reported at $237000.0 in Q1 2024.

• On a quarterly basis, Capital Expenditures fell 89.52% year-over-year to $237000.0 in Q1 2024; TTM through Dec 2024 was $237000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $9000.0, down 96.2% from the prior year.
• Capital Expenditures for Q1 2024 stood at $237000.0, up from -$6.5 million in the prior quarter.
• Over the last five years, Capital Expenditures for PYXS reached as high as $5.0 million in Q4 2022 and fell as low as -$6.5 million in Q4 2023.
• Historically, Capital Expenditures has averaged $673909.1 across 4 years, with a median of $340000.0 in 2022.
• On a YoY basis, Capital Expenditures climbed as much as 6875.38% in 2023 and fell as far as 228.78% in 2023.
• Year by year, Capital Expenditures stood at $371000.0 in 2021, then soared by 1258.22% to $5.0 million in 2022, then tumbled by 228.78% to -$6.5 million in 2023, then soared by 103.65% to $237000.0 in 2024.
• Per Business Quant data, the three most recent Capital Expenditures figures were $237000.0 in Q1 2024, -$6.5 million in Q4 2023, and $61000.0 in Q3 2023.